anticoagulation

The use of oral anticoagulation at the time of acute COVID-19 infection and subsequent development of long-COVID/post-acute sequelae of SARS-CoV-2 infection Frost, Freddy; Rivera-Caravaca, José Miguel; Lip, Gregory Y. H. Long COVID (LC) or post-acute sequelae of SARS-CoV-2 infection (PASC) is...

There have been a number of case studies suggesting anti-coagulants are useful treatments for long Covid, and a number of doctors are prescribing these, singly or as a 'triple therapy' to long Covid patients, including children. The treatment has tended to be promoted along with the hypothesis...

https://www.gavinpublishers.com/article/view/long-covid-patients-successfully-treated-by--means-of-heparin-mediated-extracorporeal-ldl-precipitation-help-apheresis Many COVID-19 infected patients develop a chronic state of disease that hinders them for months or even years due to severe...

Treatment of Long Covid with Enoxaparin, 2025, Wright, Ciara PhD, Kell, Douglas PhD, Pretorius, Resia PhD. Putrino, David PhD Abstract Background and Purpose: Long COVID is a complex multisystemic disease state, which represents a huge economic and health burden worldwide. Hypercoagulation and...

Anticoagulation Among Patients Hospitalized for COVID-19 The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Claire L. Vale ; Peter J. Godolphin ; David J. Fisher ; Julian P.T. Higgins ; Alexandra McAleenan ; Francesca Spiga ; Tobias Tritschler ; Pedro Gabriel...

Patient-Reported Treatment Outcomes in ME/CFS and Long COVID Martha Eckey; Peng Li; Braxton Morrison; Ronald W Davis; wenzhong xiao Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID are persistent multi-system illnesses affecting many patients. With no known effective...

Circulating microaggregates as biomarkers for the Post‐COVID syndrome Hermann; Lisch; Gerth; Wick; Fries; Wick CoVID-19 can develop into Post-COVID syndrome of potentially high morbidity, with procoagulation and reactivation of dormant viral infections being hypothesized pathophysiological...

Prophylactic rivaroxaban in the early post-discharge period reduces the rates of hospitalization for atrial fibrillation and incidence of sudden cardiac death during long-term follow-up in hospitalized COVID-19 survivors Fiedler, Lukas; Motloch, Lukas J.; Dieplinger, Anna-Maria; Jirak, Peter...

Background: Fibrin(ogen) amyloid microclots and platelet hyperactivation are key pathological findings in patients with acute COVID-19 infection and also in those with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). These pathologies may represent a suitable target for pharmacological...

Anticoagulation Strategies in Non-Critically Ill Patients Hospitalized with COVID-19: A Randomized Clinical Trial Gregg W. Stone ... Mercedes Villareal Garcia Lomas Background Prior studies of therapeutic-dose anticoagulation in patients with COVID-19 have reported conflicting results...

Financial Times article: Blood clot drug totally ineffective as post-Covid treatment, research finds Results from UK-wide trials on anticoagulant Apixaban set to change protocols around the world A drug to reduce blood clots, widely prescribed to Covid-19 patients after discharge from hospital...

Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors Motloch LJ, Jirak P, Mirna M, Fiedler L, Davtyan PA, Lakman IA, Gareeva DF, Tyurin AV, Gumerov RM, Matskeplishvili ST...